Life Sciences Tools and Instruments Sector Outlook — September 2026
This sector outlook covers Life Sciences Tools and Instruments: platform business models, forward valuation multiples and precedent transaction terms. Written for investors and management teams assessing where recurring revenue and workflow ownership align with valuation.
For information only. Not an appraisal or a fairness opinion.
What moved since: Life Sciences Tools and Instruments M&A update, 14–28 September 2026
Key figures
- Cell & Gene Therapy Platforms
- 8.8x
- EV/Revenue, CY2027E
- Laboratory Monitoring Instruments
- 3.0x
- EV/Revenue, CY2027E
- Sector Median Multiple
- 5.2x
- EV/Revenue, CY2027E, rated names
- High End of Precedent Deal Range
- 26.6x
- LTM at announcement
Read the report
1 / 21 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES TOOLS AND INSTRUMENTS
Executive summary
Life Sciences Tools and Instruments spans platform models with different recurring-revenue and workflow-ownership profiles, and a wide valuation range persists even on a forward-revenue basis that already credits forecast growth. Faster-growing names in the comparable set trade at a lower median multiple than slower-growing names, pointing to profitability and workflow durability as more decisive than growth alone. Precedent transaction terms range from 1.1x to 26.6x, consistent with target-specific context mattering alongside public benchmarks.
Key findings
- Cell and gene therapy platforms trade near 8.8x, lab monitoring tools near 3.0x
- Forward revenue (CY2027E) covers the comparable set more broadly than forward EBITDA
- Faster-growing names trade at 4.6x versus 6.4x for slower-growing names
- Precedent deal terms span 1.1x to 26.6x, reflecting target-specific context
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES TOOLS AND INSTRUMENTS
This is the cover page identifying the report as a Life Sciences Tools and Instruments sector outlook dated September 2026.
We're presenting our September 2026 outlook on Life Sciences Tools and Instruments, using market data and consensus estimates as of September 28, 2026 on an EV/Revenue (CY2027E) basis. That consistent lens sets up the finding we walk through next: platform model shapes how the market prices these businesses.
Everything on this page
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES TOOLS AND INSTRUMENTS Life Sciences Tools: Platforms Earn Different Prices This report shows how platform model, recurring revenue quality and workflow position align with valuation and what buyers agreed to pay. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1
- 02CONTENTS
What This Report Covers
This page lists the five numbered sections plus appendix that the report covers.
We've structured this report so the bottom line comes first: even a reader who stops after section one leaves with the full story. From there we move through the landscape, valuation and situations, precedent transactions, and strategic implications. This order lets you go as deep as you need, so the summary and the detail are both one page away.
Everything on this page
CONTENTS What This Report Covers 01 The Bottom Line Platform Economics Separate the Field 02 The Landscape Four Platform Models Carry Distinct Economics 03 Valuation & Situations The Premium Survives a Forward Revenue Lens 04 Precedent Transactions Precedent Transactions Reward Differentiated Assets 05 Strategic Implications Recurring Economics Deserve the Next Operating Dollar 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2
- 0301 · THE BOTTOM LINE
Life Sciences Tools Prices Cell and Gene Therapy Platforms Differently from Laboratory Monitoring Instruments
This page summarizes the report's core finding: cell and gene therapy platforms and laboratory monitoring instruments are priced differently.
Our valuation basis here is EV/Revenue on CY2027E consensus, covering 11 of 12 companies in the comparable set. Cell and gene therapy enabling platforms sit at 8.8x, while laboratory quality control and sterilisation monitoring instruments sit at 3.0x. That gap tracks with differences in recurring revenue and workflow position, not simply growth, so platform model is the first thing we'd check before comparing multiples. This sets the frame for everything that follows in the report.
Everything on this page
01 · THE BOTTOM LINE Life Sciences Tools Prices Cell and Gene Therapy Platforms Differently from Laboratory Monitoring Instruments The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (11 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Platform Model Travels with Valuation Cell and gene therapy enabling platforms sit at 8.8x in the middle of their range. Laboratory quality control and sterilisation monitoring instruments sit at 3.0x, with different recurring revenue and workflow profiles alongside that gap. 2 Forward Revenue Is the Practical Lens EV/Revenue on CY2027E covers 12 of 12 companies, while forward EBITDA is reported for 4 of 12. The forward lens already credits forecast growth, so a premium that remains points to durability beyond the forecast. 3 Faster Growth Sits at a Lower Valuation Among the six names at or above 7% growth, the middle valuation is 4.6x. Among the five names below 7% growth, it is 6.4x, showing that growth alone does not describe the pricing pattern. 4 Agreed Prices Span a Wide Range Recorded EV/Revenue terms extend from 1.1x for Akoya Biosciences, Inc. to 26.6x for Semler Scientific, Inc. The transaction record suggests that target context and strategic fit matter alongside public-company benchmarks. 5.2x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because only 4 of 12 names carry a meaningful forward EBITDA 8.8x Premium end EV/Revenue vs 2.2x at the discount end top quartile (n=3) against bottom quartile (n=3) on EV/Revenue — the spread the report explains 24 Transactions with disclosed terms 42 recorded in this tier · 3 told as case studies, the full list in the appendix
- 04SECTION 02
02
This divider introduces the section on the four platform models and how their economics differ.
Next we group the sector into four platform models, based on installed base, pull-through and regulated workflow exposure. This sets up the market map and landscape pages that follow.
Everything on this page
SECTION 02 02 THE LANDSCAPE Four Platform Models Carry Distinct Economics Installed base, pull-through and regulated workflow exposure shape the comparison. 02 of 06 Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4
- 0502 · MARKET MAP
The Money Sits with Platforms That Own More of the Workflow
This page groups the 12 approved companies by business segment and shows median EV/Revenue for each group.
We've grouped all 12 companies in the approved universe by business segment and calculated the median EV/Revenue on CY2027E for each group. The pattern is clear: platforms that own more of the customer's workflow command higher medians than single-point instrument providers. That's a useful screen for where recurring revenue is more likely to sit, so we'd use segment position as a first cut before looking at company-specific detail.
Everything on this page
02 · MARKET MAP The Money Sits with Platforms That Own More of the Workflow 12 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 RESEARCH AND DIAGNOSTICS INSTRUMENT PLATFORMS 3 cos median 6.4x DHR A RVTY Broad installed bases can support consumables pull-through, service revenue and exposure across research and diagnostics workflows. LAB QUALITY CONTROL AND STERILISATION MONITORING INSTRUMENTS 3 cos median 3.0x BRKR PACB CTKB Validated processes and regulated settings can support switching costs, while instrument cyclicality still matters. SPECIALTY LABORATORY INSTRUMENTATION AND CALIBRATION SYSTEMS 3 cos median 3.7x MLAB MASS LAB Specialised tools can hold critical workflow positions, with value depending on recurring attach and replacement risk. CELL AND GENE THERAPY ENABLING PLATFORMS 3 cos median 8.8x TECH TXG MXCT Exposure to translational and bioprocessing workflows can widen the path from research-use-only demand into more durable applications.
- 0602 · LANDSCAPE
Recurring Attach Separates Four Equal-Sized Platform Groups
This page describes four equal-sized platform groups separated by recurring attach.
We split the approved universe into four platform groups of similar size, using EV/Revenue medians on rated names within each. Recurring attach — how much of revenue repeats through consumables and service — is what separates them, not simply size or growth. Full company-level detail sits in the appendix, so this page is the map and the appendix is the detail. That separation is what we build on through the rest of the valuation section.
Everything on this page
02 · LANDSCAPE Recurring Attach Separates Four Equal-Sized Platform Groups Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Research and diagnostics instrument platforms 3 25% 6.4x Danaher Corporation (DHR) · Agilent Technologies, Inc. (A) · +1 more Installed breadth supports resilience. The group spans research and diagnostics workflows and sits at 6.4x. Its commercial quality rests on installed base utilisation, consumables pull-through and service attach. Lab quality control and sterilisation monitoring instruments 3 25% 3.0x Bruker Corporation (BRKR) · Pacific Biosciences of California, Inc. (PACB) · +1 more Pull-through is the test. The group sits at 3.0x. Validated workflows can support retention, but placement growth carries less weight when recurring consumables and service do not follow. Specialty laboratory instrumentation and calibration systems 3 25% 3.7x Mesa Laboratories, Inc. (MLAB) · 908 Devices Inc. (MASS) · +1 more Precision earns workflow relevance. The group sits at 3.7x across the names with an estimate. Its standing depends on whether specialised tools own a durable workflow step or remain exposed to replacement. Cell and gene therapy enabling platforms 3 25% 8.8x Bio-Techne Corporation (TECH) · 10x Genomics, Inc. (TXG) · +1 more Regulated migration expands durability. The group sits at 8.8x. Research-use-only platforms gain a broader commercial frame when assay menus, workflow ownership and bioprocessing relevance deepen.
- 07SECTION 03
03
This divider introduces the section testing whether the valuation premium holds on a forward revenue basis.
We now test whether the premium for certain platforms survives once forecast growth is already credited. The range stays wide even on that forward lens, which is the question the next few pages answer.
Everything on this page
SECTION 03 03 VALUATION & SITUATIONS The Premium Survives a Forward Revenue Lens The range remains wide after forecast growth is already reflected. 03 of 06 Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7
- 0803 · PUBLIC MARKET VALUATION
The Premium End Retains Its Lead After Forecast Growth Is Credited
This page ranks all 11 rated companies by EV/Revenue (CY2027E) against a sector median of 5.2x.
We use EV/Revenue on CY2027E because only 4 of the 12 companies carry a meaningful forward EBITDA estimate, so revenue is the more complete lens. The sector median sits at 5.2x, and the premium tier holds its lead even after forecast growth is already reflected in the multiple. That persistence is the signal: it points to durability beyond next year's growth rate, which is exactly what we'd want a buyer or investor to underwrite. The tier zones here are our own groupings, cut at the rated set's quartiles.
Everything on this page
03 · PUBLIC MARKET VALUATION The Premium End Retains Its Lead After Forecast Growth Is Credited EV / Revenue (CY2027E) · all 11 rated companies, sorted descending · sector median 5.2x · EV/Revenue is the lens because only 4 of 12 names carry a meaningful forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (11 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 8.8x CORE · median 5.2x DISCOUNT · median 2.2x Sector median 5.2x WHAT SEPARATES THE TWO ENDS The range stays wide. The premium-end middle is 8.8x versus 2.2x at the discount end. A forward revenue lens already includes forecast growth, so the remaining spread points to differences in expected durability and platform quality. Recurring mix carries weight. Installed base quality, consumables attach and service revenue give owners a clearer way to frame revenue durability through instrument purchasing cycles. Workflow position matters. Validated methods, proprietary assays and sample-to-answer ownership can support switching costs that a point tool may not carry.
- 0903 · VALUATION DRIVERS
Profitability Separates the Two Ends: Names Above the 30% Margin Line Carry 6.4x Against 3.3x Below It
This page compares median EV/Revenue across revenue-growth and EBITDA-margin cohorts.
Splitting rated names at their covered median growth rate, the faster-growing cohort sits at 4.6x and the slower-growing cohort at 6.4x — growth alone doesn't explain the pattern. Splitting instead on margin, names above the 30% EBITDA margin line carry 6.4x against 3.3x below it, a wider and cleaner split. We read this as an association in the data, not a causal claim, but it tells us where to focus: profitability tracks valuation more tightly here than top-line growth. That's a useful screen for prioritising margin improvement alongside growth investment.
Everything on this page
03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 30% Margin Line Carry 6.4x Against 3.3x Below It Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=6; slower n=5; higher-margin n=3; lower-margin n=3). Driver readings are NeuraCap views on the supplied data — association, not causation. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 7% · EBITDA-margin split at 30% The Faster-Growth Group Sits Lower Among the six names at or above the growth split, valuation sits below the five-name group beneath it. The observed pattern is association, not evidence that growth reduces value. Pull-Through Sharpens Revenue Quality Placement growth is more commercially meaningful when installed base utilisation, consumables reorders and service attach rise alongside it. Workflow Ownership Supports Durability Platforms embedded in validated methods and operating procedures can carry higher switching costs than replaceable components within another provider's workflow. Regulated Migration Changes the Frame Movement from research-use-only into clinical or bioprocessing workflows can broaden demand durability while increasing regulatory and execution requirements.
- 1003 · SITUATION MAP
Value Sits with Revenue That Repeats, and the Four Situations Reach It Different Ways
This page maps companies into four situations based on EV/Revenue versus the sector median and growth versus the covered median.
We cut the comparable set on EV/Revenue against the 5.2x sector median and on revenue growth against the 7% covered median, producing four situations. This is a characterisation of where each company sits today, not a recommendation to buy or sell any security. What it shows is that value concentrates with revenue that repeats, and different situations reach that outcome through different paths. That's the setup for the agenda on the next page.
Everything on this page
03 · SITUATION MAP Value Sits with Revenue That Repeats, and the Four Situations Reach It Different Ways Cut on EV / Revenue vs the sector median (5.2x) (rows) and revenue growth vs the covered median (7%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Credited and Delivering Above-median multiple · above-median revenue growth 3 names Danaher Corporation (DHR) · 10x Genomics, Inc. (TXG) · Pacific Biosciences of California, Inc. (PACB) The multiple already assumes execution; the agenda is defending what the market has credited. Premium Ahead of the Operating Case Above-median multiple · below-median revenue growth 3 names Agilent Technologies, Inc. (A) · Revvity, Inc. (RVTY) · Bio-Techne Corporation (TECH) The premium outruns the operating measure beneath it; the gap wants an answer before the market asks the question. Operating Case Ahead of the Price Below-median multiple · above-median revenue growth 3 names Cytek Biosciences, Inc. (CTKB) · 908 Devices Inc. (MASS) · MaxCyte, Inc. (MXCT) The operating case runs ahead of the price — the re-rating conversation lives in this cell. Priced for What It Is Below-median multiple · below-median revenue growth 2 names Bruker Corporation (BRKR) · Mesa Laboratories, Inc. (MLAB) Priced as what it is today; ownership, structure and capital-allocation questions dominate.
- 1103 · THE AGENDA
Mix, Pricing and Retention Are the Options That Shift Revenue Toward What Repeats
This page frames mix, pricing and retention as the operating questions that shift revenue toward recurring revenue.
Based on the situations we just mapped, we frame three questions an owner or acquirer should work through: product mix, pricing and retention. These are observations grounded in the cohort data, not a recommendation, and they're the practical levers for shifting revenue composition toward what repeats. Getting this right is what moves a company from one situation on the map to a stronger one over time.
Everything on this page
03 · THE AGENDA Mix, Pricing and Retention Are the Options That Shift Revenue Toward What Repeats NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Deepen Consumables Attach The operating choice is where menu expansion, utilisation and service coverage can raise pull-through from the installed base. What changes the answer: The answer changes when placements rise without corresponding reorder or service activity. Own More of the Workflow Build-versus-buy decisions should test whether an adjacent assay, instrument or service step strengthens sample-to-answer relevance. What changes the answer: The answer changes when customers can replace the product without changing a validated workflow. Advance Regulated Migration The key allocation question is where research-use-only products have a credible path into clinical or bioprocessing demand. What changes the answer: The answer changes when regulatory cost and adoption timing outweigh the expected improvement in revenue durability. Rebalance End-Market Exposure Revenue mix across academic, biopharma, applied and clinical demand shapes sensitivity to funding and capital-budget cycles. What changes the answer: The answer changes when concentration in one funding cycle begins to constrain placement cadence or book-to-bill.
- 12SECTION 04
04
This divider introduces the section on precedent transactions and how agreed values varied.
We now turn to the deal record: precedent transactions in this sector show agreed values that vary widely with platform maturity and strategic context. The case studies and full list that follow show what that variation looks like in practice.
Everything on this page
SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Reward Differentiated Assets Agreed values vary widely across platform maturity and strategic context. 04 of 06 Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12
- 1304 · DEAL CASE STUDIES
Agreed Transaction Values Reflect Very Different Strategic Contexts
This page walks through three of the 24 disclosed-terms transactions as case studies.
We've selected three transactions from the 24 with disclosed terms to illustrate how differently strategic context can shape an agreed price; the complete list sits in the appendix. Recorded terms include multiples from 1.1x up to 26.6x, and deal multiples here are LTM at announcement, so they aren't directly comparable to the CY2027E public basis we use elsewhere. Our read on why each deal happened is our own view of the recorded evidence, not a certainty. Together, these cases show that target-specific fit matters as much as sector-wide benchmarks.
Everything on this page
04 · DEAL CASE STUDIES Agreed Transaction Values Reflect Very Different Strategic Contexts 3 of 24 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 56 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 18 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Sep-2025 $1.1B Strive, Inc. Strive, Inc. and Semler Scientific, Inc. set a high revenue reference for the transaction record. EV / LTM revenue 26.6x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The announced combination suggests Strive, Inc. saw strategic fit with Semler Scientific, Inc. The size of the agreed value indicates a substantial commitment to the combination. HOW THE TARGET WAS VALUED Semler Scientific, Inc. was valued at $1.1B and 26.6x EV/Revenue. That benchmark sits above the public peer set. Jan-2025 $92M Quanterix Corporation Quanterix Corporation paired with Akoya Biosciences, Inc. in a pending platform combination. EV / LTM revenue 1.1x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The pairing suggests adjacent platform logic between Quanterix Corporation and Akoya Biosciences, Inc. It points to the potential value of broader workflow coverage. HOW THE TARGET WAS VALUED Akoya Biosciences, Inc. was valued at $92M and 1.1x EV/Revenue. That benchmark sits below the middle of the public peer set. Jun-2026 $2M ASP Isotopes Inc. ASP Isotopes Inc. agreed a pending combination with ENDRA Life Sciences Inc. EV / LTM revenue 7.5x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The pairing suggests ASP Isotopes Inc. saw strategic fit with ENDRA Life Sciences Inc. The pending transaction adds another platform combination to the record. HOW THE TARGET WAS VALUED ENDRA Life Sciences Inc. carries a recorded value of $2M and 7.5x EV/Revenue. The revenue benchmark sits above the middle of the public peer set.
- 14SECTION 05
05
This divider introduces the section on strategic implications for platforms with recurring economics.
We close the analysis by asking where the next operating dollar is best spent: pull-through, workflow ownership and regulated migration all sharpen a platform's position. The next page sets out what that means in practice.
Everything on this page
SECTION 05 05 STRATEGIC IMPLICATIONS Recurring Economics Deserve the Next Operating Dollar Pull-through, workflow ownership and regulated migration sharpen positioning. 05 of 06 Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14
- 1505 · STRATEGIC IMPLICATIONS
Platforms with Durable Pull-Through Sit Higher in the Range
This page argues that platforms with durable pull-through sit higher in the valuation range.
Our view, drawn from the analysis in this report, is that durable pull-through — consumables, service and repeat utilisation — tracks with a higher position in the valuation range. This page frames questions for the next twelve months rather than a specific recommendation. We'd use it as a checklist for where to direct capital and management attention, so the observations here connect directly back to the data earlier in the report.
Everything on this page
05 · STRATEGIC IMPLICATIONS Platforms with Durable Pull-Through Sit Higher in the Range NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Treat Placements as the Start The commercial test is whether placements lead to utilisation, consumables reorders and service attach. Revenue quality becomes clearer when those economics move together. FOR MANAGEMENT TEAMS Fund the Durable Workflow Capital allocation should distinguish menu expansion that deepens an installed base from product expansion that adds another point tool. FOR BOARDS Choose the Value Pathway The strategic agenda is whether to deepen recurring mix, extend workflow ownership, enter regulated applications or rebalance end-market exposure.
- 16SECTION 06
06
This divider introduces the appendix covering the full comparable universe, methodology and sources.
The appendix contains the comparables detail behind every figure in the body, sets out the valuation basis used, and shows where each underlying disclosure sits. Use it to trace any number in this report back to its source.
Everything on this page
SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16
- 1706 · PUBLIC COMPARABLES (1 OF 1)
Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier
This page lists public comparables on EV/Revenue (CY2027E), grouped by valuation tier, with 11 companies rated and 1 not rated.
This page groups the 11 rated companies by valuation tier against the 5.2x sector median, with tickers linking to the underlying source. One company in the universe carries no eligible EV/Revenue and sits outside the rated set. We'd use this page as the reference table behind every multiple quoted earlier in the report, since the full field set for each name is in the companion workbook.
Everything on this page
06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (5.2x); amber marks below · 11 rated companies; 1 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 11 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥6.4x · median 8.8x · 3 companies 10x Genomics, Inc. TXG Cell and gene therapy enabling platforms $10.8B 15.9x 9% n/a n/a Bio-Techne Corporation TECH Cell and gene therapy enabling platforms $11.4B 8.8x 6% 35% 41 Revvity, Inc. RVTY Research and diagnostics instrument platforms $19.3B 6.4x 5% 31% n/a CORE — 3.2x–6.4x · median 5.2x · 5 companies Agilent Technologies, Inc. A Research and diagnostics instrument platforms $51.2B 6.4x 6% 29% n/a Danaher Corporation DHR Research and diagnostics instrument platforms $175B 6.2x 8% 31% 40 Pacific Biosciences of California, Inc. PACB Lab quality control and sterilisation monitoring… $958M 5.2x 15% n/a n/a 908 Devices Inc. MASS Specialty laboratory instrumentation and calibration… $334M 4.0x 19% n/a n/a Mesa Laboratories, Inc. MLAB Specialty laboratory instrumentation and calibration… $877M 3.3x 5% 25% n/a DISCOUNT — <3.2x · median 2.2x · 3 companies Bruker Corporation BRKR Lab quality control and sterilisation monitoring… $11.2B 3.0x 4% 18% 23 Cytek Biosciences, Inc. CTKB Lab quality control and sterilisation monitoring… $496M 2.2x 7% n/a 9 MaxCyte, Inc. MXCT Cell and gene therapy enabling platforms $35M 0.9x 18% n/a n/a
- 1806 · PRECEDENT TRANSACTIONS (1 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This page lists precedent transactions with disclosed terms, newest first, covering part of the 24 disclosed-terms deals out of 42 recorded.
This table lists transactions with disclosed terms, newest first, with deal values linking to the underlying filing. Multiples shown are LTM at announcement, so they sit on a different basis than the CY2027E public multiples used elsewhere in this report and no spread should be drawn between them. Some records carry data-quality flags noted in the source line, and transactions without a disclosed value or multiple are kept in the companion workbook rather than shown here. This is the primary reference for anyone tracing a specific deal's terms.
Everything on this page
06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 24 transactions with disclosed terms in this tier (42 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 56 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 18 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 24 transactions shown; the rest are in the companion workbook. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jun-2026 ASP Isotopes Inc. → ENDRA Life Sciences Inc. $2M 7.5x n/a ASP Isotopes Inc. agreed to acquire ENDRA Life Sciences Inc. at a recorded value of $2M and 7.5x EV/Revenue. The pairing suggests strategic fit between the two businesses. Feb-2026 n/a → Bio-Rad Laboratories, Inc. $9.0B 3.1x 20.1x The announced Bio-Rad Laboratories, Inc. transaction carries a recorded value of $9.0B, 3.1x EV/Revenue and 20.1x EV/EBITDA. Sep-2025 Strive, Inc. → Semler Scientific, Inc. $1.1B 26.6x n/a Strive, Inc. announced a combination with Semler Scientific, Inc. The agreed revenue benchmark sits above the public peer set. Jul-2025 Waters Corporation → Becton, Dickinson and Company (BD Biosciences & Diagnostic Solutions) n/a n/a 19.8x Waters Corporation announced a transaction for Becton, Dickinson and Company (BD Biosciences & Diagnostic Solutions) at 19.8x EV/EBITDA. Apr-2025 KKR & Co. Inc. → Biotage AB n/a n/a 24.5x KKR & Co. Inc. announced a transaction for Biotage AB at 24.5x EV/EBITDA, showing financial buyer participation in the transaction record. Jan-2025 Quanterix Corporation → Akoya Biosciences, Inc. $92M 1.1x n/a Quanterix Corporation agreed to acquire Akoya Biosciences, Inc. The pending combination suggests a platform adjacency thesis. Dec-2024 Deerfield Management Company, L.P. → Singular Genomics Systems, Inc. n/a 14.3x n/a Deerfield Management Company, L.P. announced a transaction for Singular Genomics Systems, Inc. at 14.3x EV/Revenue. Apr-2024 Bruker Corporation → NanoString Technologies, Inc. n/a 2.3x n/a Bruker Corporation announced a transaction for NanoString Technologies, Inc. at 2.3x EV/Revenue, suggesting a fit around adjacent life sciences workflows. Oct-2023 Thermo Fisher Scientific Inc. → Olink Holding AB (publ) $3.1B n/a n/a Thermo Fisher Scientific Inc. announced a transaction for Olink Holding AB (publ) at a recorded value of $3.1B. The pairing suggests interest in expanding assay and workflow coverage.
- 1906 · PRECEDENT TRANSACTIONS (2 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This page continues the list of precedent transactions with disclosed terms, newest first.
This is the second page of the same disclosed-terms list, continuing newest first with deal values linked to the underlying filing. The same basis notes apply: multiples are LTM at announcement, not directly comparable to the CY2027E public basis. Together, these two pages cover the transactions with disclosed terms; the remainder sit in the companion workbook. We'd use both pages side by side when comparing a specific deal to the case studies discussed earlier.
Everything on this page
06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 24 transactions with disclosed terms in this tier (42 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 56 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 18 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 24 transactions shown; the rest are in the companion workbook. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jan-2023 Berkeley Lights Inc. → IsoPlexis Corporation n/a 3.0x n/a Apr-2021 DiaSorin S.p.A. → Luminex Corporation n/a 4.1x 21.2x Feb-2019 Danaher Corporation → GE Biopharma n/a 6.7x 17.5x Dec-2018 Teledyne Technologies Incorporated → Roper Technologies, Inc. $33.0B 6.5x n/a Value shown as recorded in the filing; deal value unit unresolved. Nov-2018 Pacific Biosciences of California, Inc. → Illumina, Inc. $1.8B 4.6x n/a Value shown as recorded in the filing; deal value unit unresolved. Oct-2018 The Company → Merck KGaA-Flow Cytometry Business n/a 1.7x 19.5x Value shown as recorded in the filing; deal value unit unresolved. May-2016 Thermo Fisher Scientific Inc. → FEI Company n/a n/a 17.7x Apr-2013 Thermo Fisher Scientific Inc. → Life Technologies Corporation n/a 3.9x n/a May-2011 Thermo Fisher Scientific Inc. → Qiagen N.V. n/a 8.3x n/a Value shown as recorded in the filing; deal value unit unresolved.
- 2006 · METHODOLOGY
Sources, Assumptions and Data Quality
This page sets out the report's sources, assumptions and data-quality notes.
This page sets out how the analysis was built, what was excluded, and where each underlying disclosure sits. Every figure in this report links to the record it was taken from, and where no link is available, the appendix names the source and the basis on which it was read. Use this page as the reference point for checking any number in the report against its original filing or estimate.
Everything on this page
06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice 20 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (11 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Life Sciences Tools and Instruments and it clears the coverage gate with 12 of 12 companies (100%). EV / EBITDA, P / E are carried as a cross-check. A revenue lens is used rather than a profit multiple because forward EBITDA is reported for 4 of 12 companies. DATA QUALITY & EXCLUSIONS 41 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 489 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (488) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.
- 21
The Premium Sits with Durable Platforms, Recurring Attach and Deeper Workflow Relevance.
This closing page restates that the premium sits with durable platforms, recurring attach and deeper workflow relevance.
The premium in this sector sits with durable platforms, recurring attach and deeper workflow relevance, and that's the thread running through every section of this report. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace further.
Everything on this page
The Premium Sits with Durable Platforms, Recurring Attach and Deeper Workflow Relevance. NeuraCap AI — Life Sciences Tools and Instruments Coverage September 2026 · Prepared by NeuraCap AI · Confidential Life Sciences Tools and Instruments Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21
Sources and methodology
This report covers Life Sciences Tools and Instruments (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Life Sciences Tools and Instruments) with market data and consensus estimates as of September 28, 2026. The company universe is the 12 listed companies whose core business is Life Sciences Tools and Instruments according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Agilent Technologies, Inc. (A), Bruker Corporation (BRKR), Cytek Biosciences, Inc. (CTKB), Danaher Corporation (DHR), Standard BioTools Inc. (LAB), 908 Devices Inc. (MASS), Mesa Laboratories, Inc. (MLAB), MaxCyte, Inc. (MXCT), Pacific Biosciences of California, Inc. (PACB), Revvity, Inc. (RVTY), Bio-Techne Corporation (TECH), 10x Genomics, Inc. (TXG). The market map groups them by business vertical — Research and diagnostics instrument platforms: 3 companies (DHR, A, RVTY); Lab quality control and sterilisation monitoring instruments: 3 companies (BRKR, PACB, CTKB); Specialty laboratory instrumentation and calibration systems: 3 companies (MLAB, MASS, LAB); Cell and gene therapy enabling platforms: 3 companies (TECH, TXG, MXCT). 11 of the 12 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
Scope and company universe
This report covers Life Sciences Tools and Instruments (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Life Sciences Tools and Instruments) with market data and consensus estimates as of September 28, 2026. The company universe is the 12 listed companies whose core business is Life Sciences Tools and Instruments according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Agilent Technologies, Inc. (A), Bruker Corporation (BRKR), Cytek Biosciences, Inc. (CTKB), Danaher Corporation (DHR), Standard BioTools Inc. (LAB), 908 Devices Inc. (MASS), Mesa Laboratories, Inc. (MLAB), MaxCyte, Inc. (MXCT), Pacific Biosciences of California, Inc. (PACB), Revvity, Inc. (RVTY), Bio-Techne Corporation (TECH), 10x Genomics, Inc. (TXG). The market map groups them by business vertical — Research and diagnostics instrument platforms: 3 companies (DHR, A, RVTY); Lab quality control and sterilisation monitoring instruments: 3 companies (BRKR, PACB, CTKB); Specialty laboratory instrumentation and calibration systems: 3 companies (MLAB, MASS, LAB); Cell and gene therapy enabling platforms: 3 companies (TECH, TXG, MXCT). 11 of the 12 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
What was excluded and why
41 records failed a validation gate and never feed a statistic in this report (40 excluded from aggregate; 1 quarantined). Each exclusion, with its reason: BRKR — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CTKB — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CTKB — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CTKB — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CTKB — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CTKB — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CTKB — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LAB — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · LAB — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · LAB — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LAB — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LAB — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LAB — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · MASS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · MASS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · MASS — EBITDA 166667.0000 is below the $1000000 materiality floor; any multiple would be meaningless (effect: excluded from aggregate) · MASS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · MASS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · MASS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · MASS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · MXCT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · MXCT — Implied EBITDA margin -124.0% outside the plausible band [-100%, 80%] (effect: quarantined) · MXCT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · MXCT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · MXCT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.
Primary valuation basis and how it was chosen
Primary valuation basis: EV / Revenue on CY2027E consensus (11 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Life Sciences Tools and Instruments and it clears the coverage gate with 12 of 12 companies (100%). EV / EBITDA, P / E are carried as a cross-check. A revenue lens is used rather than a profit multiple because forward EBITDA is reported for 4 of 12 companies. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 4 of 12 companies; EV / rEVenue: 12 of 12 companies; P/E: 6 of 12 companies. 3 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 6 companies show a non-meaningful P / E denominator and are excluded from that statistic.
How the multiples and statistics are computed
Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥6.4x, Core 3.2x–6.4x, Discount <3.2x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 5.2x = median(ev_revenue CY2027E) (11 rated companies) · 8.8x = median(ev_revenue CY2027E) within Premium tier (n=3) · 5.2x = median(ev_revenue CY2027E) within Core tier (n=5) · 2.2x = median(ev_revenue CY2027E) within Discount tier (n=3) · 4.6x = median(ev_revenue CY2027E) | growth ≥ 7% (n=6) · 6.4x = median(ev_revenue CY2027E) | growth < 7% (n=5) · 6.4x = median(ev_revenue CY2027E) | EBITDA margin ≥ 30% (n=3) · 3.3x = median(ev_revenue CY2027E) | EBITDA margin < 30% (n=3) · 36% = median Rule of 40 score (revenue growth + EBITDA margin) (n=6)
Precedent transactions: what is in the record and why
The precedent record holds the M&A transactions in Life Sciences Tools and Instruments recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 42 transactions were recorded for this industry; 24 are shown. 18 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 22 × deal value unit unresolved; 31 × no evidence record; 2 × duplicate precedent id; 1 × divestiture roles reassigned. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.
Sources
Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 493 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.
Interpretation and important notice
Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.
Sources linked in the report
- DHR (sec.gov)
- A (sec.gov)
- RVTY (sec.gov)
- BRKR (sec.gov)
- PACB (sec.gov)
- CTKB (sec.gov)
- MLAB (sec.gov)
- MASS (sec.gov)
- TECH (sec.gov)
- TXG (sec.gov)
- MXCT (sec.gov)
- $1.1B (sec.gov)
- $92M (sec.gov)
- $9.0B (sec.gov)
- 3.1x (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- $3.1B (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- $33.0B (sec.gov)
- $1.8B (sec.gov)
- n/a (sec.gov)
- 19.5x (sec.gov)
- n/a (sec.gov)
- sec.gov (488) (sec.gov)
- home.treasury.gov (1) (home.treasury.gov)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- M&A Update · 29 September 2026Managed Health Care M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Managed Health Care Sector Outlook — September 2026
- M&A Update · 29 September 2026Medical Devices M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Medical Devices Sector Outlook — September 2026
Want this analysis for a company in Life Sciences Tools and Instruments?
Company valuation reports run the same method against a single business — public or private.
